Studies to test whether these SARS-CoV-2 variant-induced COVID-19 triggers the excess synthesis of GCS and the corresponding development of glycosphingolipids, glycosphingolipids-specific IgG antibodies, and complement activation in patients with COVID-19 and GD patients with COVID-19 are also needed. This evidence concerns the gene UGCG and COVID-19.